Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.

MECHANISM OF ACTION

THE FIRST TROP-2-DIRECTED ADC: TRODELVY DELIVERS A POTENT TOPOISOMERASE 1 INHIBITOR TO mTNBC TUMORS1

Trop-2 is a surface protein frequently expressed by many cancers, including approximately 90% of TNBC tumors2*

Trop-2 biomarker testing is not required for use with TRODELVY

TRODELVY binds to the antigen Trop-2 and delivers and concentrates a potent cytotoxic into tumor tissue3

The proposed mechanism of action is based on preclinical data, which may not correlate with clinical outcomes.

The proposed mechanism of action (MOA) of TRODELVYᵀᴹ that highlights, a humanized monoclonal antibody, cytotoxicity, and a hydrolysable linker
 

Humanized monoclonal antibody1

Binds to Trop-2, the trophoblast cell-surface antigen-2
 

Hydrolysable linker1

  • Links the humanized monoclonal antibody to SN-38
  • Hydrolysis of the linker releases SN-38 to kill tumor cells
 

Cytotoxic1

The payload of TRODELVY is SN-38, a topoisomerase inhibitor that prevents repair of DNA damage and leads to apoptosis and cell death

TRODELVY has a high drug-to-antibody ratio, with an average of 7 to 8 molecules of SN-38 per antibody molecule.1

 
  • ADCs use a monoclonal antibody to deliver an attached cytotoxic drug into tumors4
  • Pharmacology data suggest that, once inside the tumor, the linker connecting the antibody to the cytotoxic is cleaved, releasing the active drug4

*As measured by immunohistochemical (IHC) assay.

References: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021. 2. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35(19):2141-2148. 3. Goldenberg D, Cardillo TM, Govindan S, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6(26):22496-22512. 4. Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Biosci Rep. 2015;35(4):1-20.